Current trials: Hodgkin Lymphoma9

The following clinical trials are currently offered in Germany in this group. More about Hodgkin Lymphoma

9 matching trials

OncoPhysRecruiting

OncoPhys Study: Investigating Physical Activity in Cancer Patients Using Questionnaires, Activity Trackers, and Patients

Physical activity can improve treatment outcomes for cancer patients. However, the accuracy of methods used to measure physical activity can vary greatly. The goal of the OncoPhys study is to compare the results of physical activity measurements obtained using a questionnaire and an activity tracker. Women and men aged 18 and older with lymphoma, pancreatic cancer, or colorectal cancer are eligible to participate in this study.

18 years and older

EMBrACeRecruiting

Living Well-Informed After a Hodgkin Lymphoma Diagnosis: A Study on Empowering Patients Through Information and Digital Support

Patients with Hodgkin lymphoma often have many questions after their diagnosis and feel they are not sufficiently informed. Yet a good understanding of one’s own illness is an important prerequisite for making informed decisions and improving well-being. The goal of the EMBrACe study is to examine whether a specially developed, internet-based information platform for patients with Hodgkin lymphoma can improve their quality of life. Patients with a new diagnosis of Hodgkin lymphoma who have a sufficient understanding of German are eligible to participate.

18–60 years · First line · Phase IV

INDIERecruiting

Personalized immunotherapy with the checkpoint inhibitor tislelizumab for early-stage, high-risk classical Hodgkin lymphoma

Classical Hodgkin lymphoma (cHL) is a malignant disease of the lymphatic system. The disease is usually very responsive to treatment, so there is a growing effort to tailor therapy as much as possible to the individual patient, also with a view to reducing potential side effects. For this reason, novel drugs and treatment regimens are being used and tested. The goal of the INDIE study is to investigate the efficacy and safety of tislelizumab—a checkpoint inhibitor already approved for other conditions—both as a standalone treatment and in combination with chemotherapy. Women and men aged 18 and older with cHL are eligible to participate in this study.

18 years and older · First line · Phase II

RELATIVITY-069

Combination of drugs already used to treat skin cancer may offer a new treatment option for Hodgkin's and non-Hodgkin's lymphomas

Hodgkin’s and non-Hodgkin’s lymphomas are malignant diseases of the lymphatic system. New treatment options are being sought for cases in which the disease remains active or recurs despite therapy. The goal of the RELATIVITY-069 study is to investigate the safety, tolerability, and efficacy of the combination of the two drugs, relatlimab and nivolumab, which has not yet been studied for this purpose. Patients under the age of 31 with recurrent or uncontrollable Hodgkin lymphoma or non-Hodgkin lymphoma are eligible to participate in this study.

up to 30 years · Relapsed / refractory · Phase I/II

IN030121Recruiting

A registry study on the collection of data regarding disease progression, treatment methods, and clinical outcomes in HIV-associated lymphomas

Lymphomas are malignant diseases of lymphocytes (lymph node cancer), a subgroup of white blood cells. People with HIV are significantly more likely to develop lymphoma due to their weakened immune system. The aim of this study is to collect data on disease progression, treatments, and clinical outcomes for HIV-associated lymphomas. Patients with HIV infection who have been diagnosed with a malignant lymphoma since January 1, 2010, are eligible to participate.

18 years and older

PRIMAVERARecruiting

AZD3470, a novel drug for the treatment of Hodgkin lymphoma (recurrence or persistent disease activity)

Classical Hodgkin lymphoma (cHL) is a malignant disease of the lymphatic system. While established standard treatments are available, the disease may still relapse or remain active (refractory). New medications are being sought for these cases. The goal of the PRIMAVERA study is to investigate the safety, tolerability, and efficacy of the new drug AZD3470. Patients aged 15 and older with cHL who have undergone at least three prior treatments are eligible to participate.

15 years and older · Relapsed / refractory · Phase I/II

MK-3475-051Recruiting

Does treatment with pembrolizumab (a checkpoint inhibitor) provide additional benefit for various types of previously treated cancers in children and adolescents?

Pembrolizumab is a so-called checkpoint inhibitor—a specific type of immunotherapy that is already approved for various types of cancer, including in children. However, experience with this treatment in children and adolescents has been limited so far. The goal of the study is to investigate the safety and efficacy of pembrolizumab in children and adolescents with advanced cancer. Children and adolescents between 6 months and 18 years of age with advanced solid tumors (e.g., kidney cancer), skin cancer (melanoma), or blood cancer (lymphoma) are eligible to participate. A prerequisite is that the disease has been previously treated and has recurred or does not respond to standard therapy (refractory). The central nervous system must not be involved.

0–17 years · Relapsed / refractory · Phase I/II

SGN35C-001

Study to Evaluate the Safety, Efficacy, and Dosage of the New Drug PF-08046044/SGN-35C in Patients with Advanced Lymphoma

Cancers of the lymphatic system (lymphomas) include, among others, classical Hodgkin lymphoma, peripheral T-cell lymphoma, diffuse large B-cell lymphoma, and anaplastic large cell lymphoma. Many patients initially respond well to treatment but later experience relapses or develop resistance to standard treatment (refractory). Treatment options are particularly limited for patients who have undergone multiple prior treatments. The goal of the study is to investigate the safety, tolerability, and optimal dosage of the new active ingredient PF-08046044/SGN-35C in these advanced lymphomas. This is a so-called antibody-drug conjugate (ADC). Eligible participants are patients 18 years of age or older with advanced lymphomas for whom previous therapies have not been sufficiently effective and for whom no suitable standard treatment is currently available.

18 years and older · First line · Phase I

MK-3475A-F65Recruiting

Study of the subcutaneous administration of pembrolizumab in combination with hyaluronidase in patients with relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

The administration of pembrolizumab as an infusion is an approved treatment for relapsed or refractory classical Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma (PMBCL). Subcutaneous administration (under the skin), however, has not yet been approved for treatment. The goal of the MK 3475A-F65 study is to investigate the efficacy, safety, and pharmacokinetics of subcutaneous pembrolizumab in combination with hyaluronidase. Women and men aged 18 and older with relapsed or refractory cHL or PMBCL are eligible to participate in this study.

18 years and older · Relapsed / refractory · Phase II